One hundred years of animal virology.

Rott, R.; Siddell, St.

doi:10.1099/0022-1317-79-11-2871

Cited by 12 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At first, experiments were carried out to exclude the possibility of the FMDV genome being unable to competently replicate in the presence of the GFP sequence. To do this, BHK-21 cells were transfected with full-length RNA prepared from the GFP-FMDV infectious copy plasmid, and a subset was subsequently treated with guanidine-HCl, a potent inhibitor of FMDV replication (De Palma et al , 2008; Rott & Siddell, 1998). Fig.…”

Section: Resultsmentioning

confidence: 99%

“…In 1898, FMDV was the first animal disease shown to be caused by a virus (Rott & Siddell, 1998). Over a century of active investigation has led to the elucidation of many aspects of the FMDV life cycle; however, critical knowledge about virus–host interactions is still lacking, including the complete identification of host cell types permissive to infection and the characterization of viral dissemination following known routes of natural infection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An infectious recombinant foot-and-mouth disease virus expressing a fluorescent marker protein

Seago

Juleff

Moffat

et al. 2013

Journal of General Virology

View full text Add to dashboard Cite

Foot-and-mouth disease virus (FMDV) is one of the most extensively studied animal pathogens because it remains a major threat to livestock economies worldwide. However, the dynamics of FMDV infection are still poorly understood. The application of reverse genetics provides the opportunity to generate molecular tools to further dissect the FMDV life cycle. Here, we have used reverse genetics to determine the capsid packaging limitations for a selected insertion site in the FMDV genome. We show that exogenous RNA up to a defined length can be stably introduced into the FMDV genome, whereas larger insertions are excised by recombination events. This led us to construct a recombinant FMDV expressing the fluorescent marker protein, termed iLOV. Characterization of infectious iLOV-FMDV showed the virus has a plaque morphology and rate of growth similar to the parental virus. In addition, we show that cells infected with iLOV-FMDV are easily differentiated by flow cytometry using the inherent fluorescence of iLOV and that cells infected with iLOV-FMDV can be monitored in real-time with fluorescence microscopy. iLOV-FMDV therefore offers a unique tool to characterize FMDV infection in vitro, and its applications for in vivo studies are discussed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

An infectious recombinant foot-and-mouth disease virus expressing a fluorescent marker protein

Seago

Juleff

Moffat

et al. 2013

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…From the second half of the 19th century, on the account of the increase of animal trade due to the development of new transport routes (O'Rourke and Williamson, 2002), the disease became more important and started to cause severe economic losses. In Germany, in 1897, a commission had been set up by the Prussian Ministry of Culture, following a request from the ''Partei der Landwirte'' of the Reichstag to set up measures of FMD control (Rott and Siddell, 1998). One year later, Friedrich Loeffler and Paul Frosch wrote in their report that the causative agent of FMD was neither a known bacterium nor a toxin but an ''ultravisible, ultrafilterable substance'' (Loeffler and Frosch, 1897), and described thereby the first animal virus, foot-and-mouth disease virus (FMDV).…”

Section: History and Impact Of Foot-and-mouth Diseasementioning

confidence: 99%

Understanding the molecular epidemiology of foot-and-mouth-disease virus

Klein

2009

Infection, Genetics and Evolution

View full text Add to dashboard Cite

The use of molecular epidemiology is an important tool in understanding and consequently controlling FMDV. In this review I will present basic information about the disease, needed to perform molecular epidemiology. I will give a short introduction to the history and impact of foot-and-mouth disease, clinical picture, infection route, subclinical and persistent infections, general aspects of the transmission of FMDV, serotype-specific epidemiological characteristics, field epidemiology of FMDV, evolution and molecular epidemiology of FMDV. This is followed by two chapters describing the molecular epidemiology of foot-and-mouth disease in global surveillance and molecular epidemiology of foot-and-mouth disease in outbreak investigation.

show abstract

“…1898: viruses are discovered as “minute living things capable of reproducing themselves .” After the pioneering work of Adolf Eduard Mayer, Dmitri Ivanovsky, and Martinus Beijerinck, two German researchers, Friedrich Loeffler and Paul Frosch, were the first to contradict the “contagium vivum fluidum” (contagious living fluid) hypothesis to define a virus (the foot-and-mouth disease virus) as a tiny particle and to suggest that “the causative agents of numerous other infectious diseases of man and animals may also belong to this group of minute organisms” (1). Thus, at the beginning of the 20th century, the door opened to a new and exciting research area: virology.…”

Section: Introductionmentioning

confidence: 99%

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers

et al. 2017

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) and leukemia are among the most common cancers worldwide. While the treatment of NHL/leukemia of B-cell origin has much progressed with the introduction of targeted therapies, few treatment standards have been established for T-NHL/leukemia. As presentation in both B- and T-NHL/leukemia patients is often aggressive and as prognosis for relapsed disease is especially dismal, this cancer entity poses major challenges and requires innovative therapeutic approaches. In clinical trials, oncolytic viruses (OVs) have been used against refractory multiple myeloma (MM). In preclinical settings, a number of OVs have demonstrated a remarkable ability to suppress various types of hematological cancers. Most studies dealing with this approach have used MM or B- or myeloid-cell-derived malignancies as models. Only a few describe susceptibility of T-cell lymphoma/leukemia to OV infection and killing. The rat H-1 parvovirus (H-1PV) is an OV with considerable promise as a novel therapeutic agent against both solid tumors (pancreatic cancer and glioblastoma) and hematological malignancies. The present perspective article builds on previous reports of H-1PV-driven regression of Burkitt’s lymphoma xenografts and on unpublished observations demonstrating effective killing by H-1PV of cells from CHOP-resistant diffuse large B-cell lymphoma, cutaneous T-cell lymphoma, and T-cell acute lymphoblastic leukemia. On the basis of these studies, H-1PV is proposed for use as an adjuvant to (chemo)therapeutic regimens. Furthermore, in the light of a recently completed first parvovirus clinical trial in glioblastoma patients, the advantages of H-1PV for systemic application are discussed.

show abstract

One hundred years of animal virology.

Cited by 12 publications

References 0 publications

An infectious recombinant foot-and-mouth disease virus expressing a fluorescent marker protein

An infectious recombinant foot-and-mouth disease virus expressing a fluorescent marker protein

Understanding the molecular epidemiology of foot-and-mouth-disease virus

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers

Contact Info

Product

Resources

About